## Abstract The rationale for immunosuppressive therapy of thrombotic thrombocytopenic purpura (TTP) was established by observations that TTP may be caused by autoantibodies to ADAMTS13. Patients with high‐titer autoantibodies to ADAMTS13 may have a higher mortality, and survivors may require prolo
The NHLBI Clinical Trials Network in transfusion medicine and hemostasis: An overview
✍ Scribed by Walter H. Dzik
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 65 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Transfusion Medicine is a broad discipline that affects the health care of patients from many medical disciplines. Despite the large impact of transfusion therapies on the management of patients with a variety of diseases, there are few clinical trials that evaluate the indications or the effectiveness of transfusion therapies. To respond to this need for better clinical data, the National Heart Lung and Blood Institute of the National Institutes of Health established a clinical trials network in Transfusion Medicine and Hemostasis. Following a competitive selection process, 17 university medical centers and a data coordinating center joined together to collaboratively address clinical questions in transfusion medicine and hemostasis. The activities, organization, and scope of the network is described below. Examples of clinical trials currently in the network “pipeline” are briefly summarized as an overview to more detailed presentations given elsewhere in this symposium. J. Clin. Apheresis 2006. 21:57–59, © 2006 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES